Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
CC transcript
Inv. presentation
SALIX PHARMACEUTICALS LTD (SLXP) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/02/2015 8-K Quarterly results
Docs: "FORM 8-K",
"Salix Pharmaceuticals Reports 4Q2014 and FY2014 Results"
11/06/2014 8-K Quarterly results
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ¨ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ¨ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Item 2.02. Results of Operations and Financial Condition. On November 6, 2014, Salix Pharmaceuticals, Ltd. issued a press release announcing its operating results for the third quarter ended September 30, 2014. A copy of the press release is attached hereto as Exhibit 99.1. The informatio...",
"Salix Pharmaceuticals Reports 3Q2014 Results"
08/07/2014 8-K Quarterly results
Docs: "Salix Pharmaceuticals Reports 2Q2014 Results"
11/07/2013 8-K Quarterly results
Docs: "Agreement and Plan of Merger, among Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Willow Acquisition Sub Corporation and Santarus, Inc",
"Tender and Support Agreement, among Salix Pharmaceuticals, Ltd., Willow Acquisition Sub Corporation and the stockholders listed therein",
"SALIX PHARMACEUTICALS REPORTS 3Q2013 RESULTS 29% Increase in Year-over-Year 3Q Product Revenue 24% Increase in Year-over-Year 3Q XIFAXAN ® 550 mg Prescriptions 53% Increase in Year-over-Year 3Q APRISO ® Prescriptions 28% Increase in Year-over-Year 3Q RELISTOR ® Prescriptions RELISTOR Advisory Committee Scheduled for March 10-11, 2014 XIFAXAN, FULYZAQ ® and RELISTOR Intellectual Property Positions Strengthened",
"SALIX PHARMACEUTICALS TO ACQUIRE SANTARUS Solidifies Position as Largest U.S. Gastroenterology-Focused Specialty Pharmaceutical Company Provides Salix with an Experienced Specialty Sales Force to Significantly Expand Gastrointestinal Product Sales Increases Commercial Presence in Gastroenterology, Hepatology and Colorectal Surgery Estimated 2013 Pro Forma Total Product Revenue of $1.3 Billion Greatly Increases Scale and Revenue Diversification Expected to be Immediately and Significantly Accretive Expected to Generate Strong EBITDA and Cash from Operations Leading to Rapid Debt Repayment"
08/08/2013 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 2Q2013 RESULTS 30% Increase in Year-over-Year 2Q Product Revenue 26% Increase in Year-over-Year 2Q XIFAXAN ® 550 mg Prescriptions 45% Increase in Year-over-Year 2Q APRISO ® Prescriptions 48% Increase in Year-over-Year 2Q RELISTOR ® Prescriptions FDA to Hold Advisory Committee Meeting to Review Relistor sNDA for Opioid-Induced Constipation in Patients with Chronic Pain Worldwide Rights to Olon's Intellectual Property Relating to Amorphous Rifaximin Acquired Statistically Significant Results Achieved in Two Phase 3 Studies for Budesonide Foam in the Treatment of Active to Moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis FULYZAQ™ Launched for Symptomatic Relief of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy Initiation of Phase 2 Stu..."
11/07/2012 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 3Q2012 RESULTS Management Maintains 2012 Revenue Guidance of $735 Million And Increases Guidance for Adjusted Net Income to $200 Million or $3.13, Per Share, Fully Diluted 27% Increase in Year-over-Year 3Q Product Revenue 20% Increase in Year-over-Year 3Q XIFAXAN ® Prescriptions on a Milligram Basis 24% Increase in Year-over-Year 3Q APRISO ® Prescriptions 89% Increase in Year-over-Year 3Q RELISTOR ® Prescriptions"
08/08/2012 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 2Q2012 RESULTS Management Confirms 2012 Revenue Guidance of $735 Million Raises 2012 Adjusted Net Income to $183 Million or $2.86 Fully Diluted 36% Increase in Year-over-Year 2Q Product Revenue 22% Increase in Year-over-Year 2Q XIFAXAN ® Prescriptions on a Milligram Basis 27% Increase in Year-over-Year 2Q APRISO ® Prescriptions 89% Increase in Year-over-Year 2Q RELISTOR ® Prescriptions"
05/07/2012 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 1Q2012 RESULTS 62% Increase in Year-over-Year 1Q Product Revenue 27% Increase in Year-over-Year 1Q XIFAXAN ® Prescriptions on a Milligram Basis 36% Increase in Year-over-Year 1Q APRISO ® Prescriptions Completed Placement of $690 Million of Senior Convertible Notes Initiated XIFAXAN Retreatment Trial for Irritable Bowel Syndrome with Diarrhea"
11/08/2011 8-K Form 8-K - Current report
08/08/2011 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 2Q2011 RESULTS Contact: Adam C. Derbyshire G. Michael Freeman Executive Vice President Associate Vice President, Investor Relations and Chief Financial Officer and Corporate Communications 919-862-1000 919-862-1000 SALIX PHARMACEUTICALS REPORTS 2Q2011 RESULTS 42% Increase in Year-over-Year 2Q Product Revenue 78% Increase in Year-over-Year 2Q XIFAXAN ® Prescriptions on a Milligram Basis Management Reiterates 2011 Guidance: Revenue of $520 Million and PreTax Income of $110 Million XIFAXAN IBS Retreatment Study Expected to be Initiated Late 2011/Early 2012 RELISTOR ® Subcutaneous Injection for Treatment of Opioid-Induced Constipation in Chronic, Non-Cancer Pain -s NDA Submitted June 27 RELISTOR Oral Tablets for the Treatment of Opioid-Induced Constipation in Chro..."
05/05/2011 8-K Form 8-K - Current report
02/28/2011 8-K Form 8-K - Current report
08/09/2010 8-K Form 8-K - Current report
05/10/2010 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 1Q2010 RESULTS XIFAXAN ® 550 mg for Hepatic Encephalopathy Gains FDA Approval XIFAXAN 550 mg Phase 3 Data Demonstrate Acute and Sustained Relief of Non-C IBS Symptoms"
03/09/2010 8-K Form 8-K - Current report
11/09/2009 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 3Q2009 RESULTS METOZOLV™ ODT Receives FDA Marketing Approval XIFAXAN ® Prescriptions Increase 15% Year-over-Year Rifaximin Demonstrates Statistical Significance in Two Phase 3 Trials for Non-Constipation Irritable Bowel Syndrome Rights Acquired for Bioadhesive Technology for Extended Release Rifaximin Product"
05/05/2009 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 1Q2009 RESULTS MOVIPREP Prescriptions Increase 92% Year-over-Year XIFAXAN Prescriptions Increase 11% Year-over-Year Rifaximin Phase 3 non-C IBS Studies Complete Enrollment Progress in FDA Review of Three NDAs",
"SALIX PHARMACEUTICALS TO PRESENT AT BANK OF AMERICA AND MERRILL LYNCH CONFERENCE"
03/10/2009 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 4Q2008 AND FY2008 RESULTS XIFAXAN and Bowel Cleanser Revenue Increases 28% Over 2007 APRISO™ Granted FDA Marketing Approval Rifaximin Pivotal Phase 3 Results in Hepatic Encephalopathy are Highly Statistically Significant Enrollment for Rifaximin Pivotal Phase 3 Studies in Non-constipation Irritable Bowel Syndrome Ahead of Schedule Pipeline Further Strengthened with Acquisition of Budesonide Products and Crofelemer"
11/05/2008 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 3Q2008 RESULTS XIFAXAN and Bowel Cleanser Revenue Increases 31% Over 3Q2007 APRISO™ Granted FDA Marketing Approval Rifaximin Pivotal Phase 3 Results in Hepatic Encephalopathy are Highly Statistically Significant Revised ACG Guidelines for IBS Incorporate Rifaximin",
"APRISO™ GRANTED FDA MARKETING APPROVAL FOR MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS APRISO™ First and Only 5-ASA with Intellicor™ Extended-Release Delivery and 24-Hour Protection from Flare-Ups in a Once-Daily Dose"
08/04/2008 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 2Q2008 RESULTS XIFAXAN, Bowel Cleansers and Other Product Revenue Increases 16% Over 2Q2007 2008 Guidance Revised Upward to Reflect Lower Operating Expenses Rifaximin Phase 3 Non-Constipation IBS Trial Initiated"
05/06/2008 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 1Q2008 RESULTS XIFAXAN, Bowel Cleansers and Other Product Revenue Increases 11% Over 1Q2007 Rifaximin Hepatic Encephalopathy Phase 3 Enrollment Completed Budesonide Products Acquired from Dr. Falk Pharma"
03/04/2008 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 4Q2007 AND FY2007 RESULTS Bowel Cleansers, XIFAXAN and Other Product Revenue Increases 34% Over 2006 Q4 and Full Year 2007 Financial Results Impacted by $34.6 Million Non-Cash Charge Related to Introduction of Generic Balsalazide Products Balsalazide Tablet, Granulated Mesalamine and Metoclopramide-ZYDIS Progressing Toward 2008 Approvals Rifaximin Phase 2b Study Results Demonstrate Statistically Significant Improvement in Diarrhea-Associated Irritable Bowel Syndrome Pepcid OS and Metoclopramide-ZYDIS Acquired Bowel Cleansers Achieve 25% Market Share"
05/08/2007 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 1Q2007 RESULTS $59.8 Million Total Product Revenue: 43% Increase Over 2006 Net Income $2.8 Million: EPS $0.06 MOVIPREP Patent Protection Granted to 2024 PEPCID Oral Suspension Acquired DIACOL™ Licensed to Dr. Falk Pharma for Europe XIFAXAN and IBD Clinical Development Programs Progressing"
02/28/2007 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 4Q2006 AND FY2006 RESULTS $208.5 Million Total Product Revenue Increases 35% Over 2005 Net Income $31.5 Million: EPS $0.65 OSMOPREP™ and MOVIPREP Approved and Launched Bowel Cleansing Franchise Achieves 20% Market Share XIFAXAN Achieves 118% Year-Over-Year Growth in Prescription Demand SANVAR License Agreement Signed Clinical Development Pipeline Advanced"
11/07/2006 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 3Q2006 RESULTS $51.2 Million Total Product Revenue Increases 28% y-o-y Net Income $7.0 million : EPS $0.15 XIFAXAN Achieves 121% y-o-y Growth in Tablets Prescribed COLAZAL Pediatric Exclusivity Granted COLAZAL Food Effect Application Approved MOVIPREP Launched SANVAR License Agreement Signed"
08/08/2006 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 2Q2006 RESULTS $52.9 Million Total Product Revenue - 51% y-o-y Increase XIFAXAN Achieves 29% Quarterly Sequential Prescription Growth GAAP Income of $6.9 Million : Non-GAAP Income of $7.8 Million GAAP EPS of $0.14 : Non-GAAP EPS of $0.16 XIFAXAN Patent Coverage Extended to 2024 FDA Grants Marketing Approval for MOVIPREP COLAZAL and XIFAXAN Wholesaler Inventories Reduced Continuing Success in Execution of Strategy to Broaden and Diversify Revenue"
02/24/2006 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 4Q2005 AND FY2005 RESULTS 2005 Product Revenue Increases 52% Non-GAAP EPS of $0.64 : GAAP EPS of 2006 Product Revenue Guidance of $205 Million 2006 EPS Guidance of at least $0.85"
11/08/2005 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 3Q2005 RESULTS"
08/09/2005 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 2Q2005 RESULTS Total Product Revenue Increases 81% Over 2Q04 Salix Delivers $0.13 EPS"
05/11/2005 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 1Q2005 RESULTS Total Product Revenue Increases 45% Over 1Q04 Salix Delivers $0.09 EPS"
02/15/2005 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS 4Q2004 AND FY2004 RESULTS Salix Achieves Full Year Profitability and Delivers $0.18 EPS Salix Surpasses $100 Million Product Revenue 2005 Guidance of $150-$155 Million Product Revenue and at Least $0.60 EPS"
11/09/2004 8-K Quarterly results
Docs: "SALIX PHARMACEUTICALS REPORTS THIRD QUARTER 2004 RESULTS Salix Achieves Profitability and Delivers $0.19 per Share, Fully Diluted COLAZAL Guidance for 2004 Increased to $80 Million"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy